Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Bristol-Myers Squibb
>
CV Division and Celgene Acquisition
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6237979"]With Eliquis being our biggest seller and the excitement around Factor 11a I find it really difficult to imagine the logic of selling off CV. But who knows. MGMT has made poorer decisions, and there is generic eliquis just around the corner, so it’s a hard maybe?</p><p><br /></p><p>It just seems putting all eggs in the Oncology basket is extremely risky, especially with the Opdivo fails and the lack of compelling combos in IO.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6237979"]With Eliquis being our biggest seller and the excitement around Factor 11a I find it really difficult to imagine the logic of selling off CV. But who knows. MGMT has made poorer decisions, and there is generic eliquis just around the corner, so it’s a hard maybe? It just seems putting all eggs in the Oncology basket is extremely risky, especially with the Opdivo fails and the lack of compelling combos in IO.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Bristol-Myers Squibb
>
CV Division and Celgene Acquisition
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Bristol-Myers Squibb
>
CV Division and Celgene Acquisition
>